Table of Content



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Angi (Angi Pectoris) - Overview
Angi (Angi Pectoris) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Angi (Angi Pectoris) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angi (Angi Pectoris) - Companies Involved in Therapeutics Development
Angionetics Inc
Arbor Pharmaceuticals LLC
AstraZeneca Plc
Caladrius Biosciences Inc
Chong Kun Dang Holdings Corp
Coeurative Inc
Eight Plus One Pharmaceutical Co Ltd
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
Imbria Pharmaceuticals Inc
Innovative Pharmacology Research
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Merck & Co Inc
Milestone Pharmaceuticals Inc
Sigl Pharma Ltd
Trizell Ltd
TSH Biopharm Corporation Ltd
VasThera Co Ltd
XyloCor Therapeutics Inc
Angi (Angi Pectoris) - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
History of Events
AR-36 - Drug Profile
Product Description
Mechanism Of Action
BJY-802 - Drug Profile
Product Description
Mechanism Of Action
CKD-385 - Drug Profile
Product Description
Mechanism Of Action
CR-0305 - Drug Profile
Product Description
Mechanism Of Action
EG-011 - Drug Profile
Product Description
Mechanism Of Action
History of Events
encoberminogene rezmadenovec - Drug Profile
Product Description
Mechanism Of Action
History of Events
etripamil - Drug Profile
Product Description
Mechanism Of Action
History of Events
GRS - Drug Profile
Product Description
Mechanism Of Action
ivabradine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
KI-1007 - Drug Profile
Product Description
Mechanism Of Action
ninerafaxstat - Drug Profile
Product Description
Mechanism Of Action
History of Events
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ranolazine ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Angi - Drug Profile
Product Description
Mechanism Of Action
tirofiban hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
VTA-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Xow - Drug Profile
Product Description
Mechanism Of Action
History of Events
zibotentan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Angi (Angi Pectoris) - Dormant Projects
Angi (Angi Pectoris) - Discontinued Products
Angi (Angi Pectoris) - Product Development Milestones
Featured News & Press Releases
May 23, 2022: Caladrius Biosciences provides update on phase 2b FREEDOM Trial of XOW in Corory Microvascular Dysfunction
May 10, 2022: Hemostemix announces its intellectual property is back home
Apr 12, 2022: Hemostemix announces intellectual property due diligence and data audit completed
Jan 19, 2021: Caladrius Biosciences treats first patient in the phase 2b FREEDOM trial of CLBS16 for the treatment of corory microvascular dysfunction
May 14, 2020: Caladrius Biosciences reports positive full results for CLBS16 from the ESCaPE-CMD trial at SCAI 2020 Scientific Sessions
May 06, 2020: Caladrius Biosciences announces presentation of full results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Corory Microvascular Dysfunction
Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
Feb 07, 2017: FDA Grants Fast Track Desigtion To Angionetics’ Generx Product Candidate, A One-Time Gene Therapy For Corory Heart Disease
Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
Sep 12, 2016: Angionetics’ Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Corory Artery Disease
Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


List of Figures
Number of Products under Development for Angina (Angina Pectoris), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables


List of Tables
Number of Products under Development for Angina (Angina Pectoris), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Angina (Angina Pectoris) - Pipeline by Angionetics Inc, 2022
Angina (Angina Pectoris) - Pipeline by Arbor Pharmaceuticals LLC, 2022
Angina (Angina Pectoris) - Pipeline by AstraZeneca Plc, 2022
Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, 2022
Angina (Angina Pectoris) - Pipeline by Chong Kun Dang Holdings Corp, 2022
Angina (Angina Pectoris) - Pipeline by Coeurative Inc, 2022
Angina (Angina Pectoris) - Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022
Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, 2022
Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, 2022
Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, 2022
Angina (Angina Pectoris) - Pipeline by Innovative Pharmacology Research, 2022
Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Angina (Angina Pectoris) - Pipeline by Merck & Co Inc, 2022
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, 2022
Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, 2022
Angina (Angina Pectoris) - Pipeline by Trizell Ltd, 2022
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, 2022
Angina (Angina Pectoris) - Pipeline by VasThera Co Ltd, 2022
Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, 2022
Angina (Angina Pectoris) - Dormant Projects, 2022
Angina (Angina Pectoris) - Dormant Projects, 2022 (Contd..1)
Angina (Angina Pectoris) - Discontinued Products, 2022